Kemokini CXCL10 i CXCL11 u patogenezi enterovirusnoga meningitisa

doctoral thesis

• Title (english): Chemokines CXCL10 and CXCL11 in the pathogenesis of enteroviral meningitis
• Author: Anamarija Čavčić
• Mentor: Goran Tešović (mentor)
• Mentor: Snježana Židovec Lepej (komentor)
• Committee member: nije dostupno (član povjerenstva)
• Granter: University of Zagreb; School of Medicine; Zagreb
• Defense date and country: 2015-09-25, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences
• Universal decimal classification (UDC): 61 - Medical sciences

Abstract

Cilj istraživanja:
Utvrditi profil kemokina CXCL10 i CXCL11 u krvi i CSL-u u djece oboljele od NPEV AM i
analizirati postojeći kemokinski gradijent te ga usporediti s onim u bolesnika iz kontrolne
skupine.
Ispitanici i metode:
U studiju je uključeno 84 bolesnika; 55 bolesnika s dokazanim NPEV AM i 29 bolesnika u
kontrolnoj skupini u kojih je upalna bolest SŽS-a isključena na temelju urednog citološkog i
biokemijskog nalaza CSL-a. Etiološka dijagnoza NPEV AM dokazana je detekcijom
enterovirusne RNA u CSL-u PCR metodom. Koncentracija kemokina određena je
standardiziranim kvantitativnim enzimskim imunotestovima.
Rezultati:
Analizirajući CSL obje skupine ispitanika, kod ispitanika s NPEV AM kemokini CXCL10
(median 21,3 ng/mL) i CXCL11 (median 0,24 ng/mL) su detektirani u višim koncentracijama
u odnosu na kontrolne ispitanike (CXCL10 medijan 0,26 ng/mL), (CXCL11 medijan 0,21
ng/mL). Serumske koncentracije CXCL10 u NPEV AM ispitanika (medijan 0,27 ng/mL) i
kontrolnih ispitanika (CXCL10 medijan 0,21 ng/mL) nisu se značajnije razlikovale. Serumske
koncentracije CXCL11 bile su u obje skupine jednake ili nešto niže u NPEV AM skupini.
Kod NPEV AM bolesnika utvrđena je pozitivna korelacija između likvorskih koncentracija
CXCL10, te CXCL10 gradijenta i pleocitoze u CSL-u.
Zaključak:
Za NPEV AM karakteristične su povišene vrijednosti kemokina CXCL10 i CXCL11 u CSLu.
Stvaranje CXCL10 koncentracijskog gradijenta između CSL-a i plazme samo je jedan od
mnoštva faktora koji, u obliku lokalnog imunološkog odgovora na NPEV infekciju, utječe na
migraciju upalnih stanica u SŽS.

Abstract (english)

Aim: To define the role of chemokines CXCL10 and CXCL11 and chemokine concentration
gradient between the peripheral blood and CNS in immunopathogenesis of non polio
enteroviral aseptic meningitis (NPEV AM).
Patients and methods: The study included 84 pediatric patients; 55 with NPEV AM and 29
controls in whom CNS infection has been excluded by negative CSF examination.The NPEV
etiology has been proven by detection of enteroviral RNA using real-time PCR method.
Chemokines were quantified by using standardized enzyme immunoassay.
Results:
Concentrations of CXCL10 (median 21.3 ng/mL) and CXCL11 (median 0.24 ng/mL) in CSF
samples of children with NPEV AM (0.27 ng/mL) were higher in comparison to control group
(CXCL10 median 0.26 ng/mL, CXCL11 median 0.21 ng/mL).
CXCL10 concentrations in the sera of NPEV AM group (median 0.27 ng/mL) and controls
(CXCL10 median 0.21 ng/mL) did not differ significantly. CXCL11 sera concentrations were
equal or slightly lower within NPEV AM group. Positive correlation between CSF CXCL10
concentrations or CXCL10 CSF-plasma gradient (median 60.9 ng/mL) and CSF pleocytosis
in patients with NPEV AM was determined as well.
Conclusion: CXCL10 and CXCL11 concentration gradient between the CSF and plasma in
children with NPEV AM suggests an important role of these chemokines in the T-cells
recruitment into the CNS and local immunoreaction.

• Keywords: medicina
• Keywords (english): medicine
• Language: croatian
• URN:NBN: urn:nbn:hr:105:787709
• Study programme: Title: Biomedicine and Health Sciences; Study programme type: university; Study level: postgraduate; Academic / professional title: doktor/doktorica znanosti, područje biomedicine i zdravstva (doktor/doktorica znanosti, područje biomedicine i zdravstva)
• Type of resource: Text
• Extent: 113 str.
• File origin: Born digital
• Access conditions: Open access
• Created on: 2023-05-05 07:41:29